Intratumor heterogeneity, which fosters tumor evolution, is a key challenge in cancer
medicine. Here, we review data and technologies that have revealed intra-tumor�…

Developments in genomic techniques have provided insight into the remarkable genetic
complexity of malignant tumours. There is increasing evidence that solid tumours may�…

Recent technologic advances have permitted higher resolution and more rapid analysis of
individual cancer genomes at the single-nucleotide level. Such advances have shown�…

Background Intratumor heterogeneity may foster tumor evolution and adaptation and hinder
personalized-medicine strategies that depend on results from single tumor-biopsy samples�…

As tumors grow, they acquire mutations, some of which create neoantigens that influence
the response of patients to immune checkpoint inhibitors. We explored the impact of�…

Clear cell renal carcinomas (ccRCCs) can display intratumor heterogeneity (ITH). We
applied multiregion exome sequencing (M-seq) to resolve the genetic architecture and�…

The interplay between an evolving cancer and a dynamic immune microenvironment
remains unclear. Here we analyse 258 regions from 88 early-stage, untreated non-small-cell�…

Spatial and temporal dissection of the genomic changes occurring during the evolution of
human non–small cell lung cancer (NSCLC) may help elucidate the basis for its dismal�…

Deciphering whether actionable driver mutations are found in all or a subset of tumor cells
will likely be required to improve drug development and precision medicine strategies. We�…

Clear-cell renal cell carcinoma (ccRCC) exhibits a broad range of metastatic phenotypes
that have not been systematically studied to date. Here, we analyzed 575 primary and 335�…